What is the Current Share Price of Sun Pharmaceutical Industries Ltd?
- Answer Field
-
Sun Pharmaceutical Industries Ltd share price is for NSE ₹ 1,804.00 & for BSE ₹ 1,804.45 as on Jun 15 2026 11:40 AM.
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
SUN PHARMACEUTICAL IND L is currently trading at ₹1804, down by ₹3.69 from the previous close. The stock touched an intraday high of ₹1818.00 and a low of ₹1797.80 during the latest trading session. Over the past one year, SUN PHARMACEUTICAL IND L has delivered a return of 7.12%, while the stock has declined 2.05% in the last one month.
| Particulars | MAR 2026 (Values in Cr) |
|---|---|
| Revenue | 4887.27 |
| Operating Expense | 4137.80 |
| Net Profit | 608.70 |
| Net Profit Margin (%) | 12.45 |
| Earnings Per Share (EPS) | 2.50 |
| EBITDA | 1391.90 |
| Effective Tax Rate (%) | 28.30 |
| Company Name | Price | P/E | P/B | Market Cap | 52 Week Low | 52 Week High |
|---|---|---|---|---|---|---|
| AMBALAL SARABHAI ENT L | 32.40 | 13.39 | 1.56 | 248.29 | 23.12 | 38.85 |
| BLISS GVS PHARMA LTD. | 438.10 | 35.56 | 3.89 | 4646.32 | 118.35 | 462.70 |
| CIPLA LTD. | 1388.80 | 29.47 | 3.25 | 112193.56 | 1165.55 | 1672.20 |
| FERMENTA BIOTECH LTD. | 338.80 | 14.94 | 2.45 | 997.12 | 256.40 | 399.00 |
| Company Name | Price | P/E | P/B | Market Cap | 52 Week Low | 52 Week High |
|---|---|---|---|---|---|---|
| AMBALAL SARABHAI ENT L | 32.40 | 22.66 | 4.17 | 248.29 | 23.12 | 38.85 |
| AMRUTAJAN HEALTH LTD | 557.75 | 25.00 | 4.35 | 1612.49 | 490.00 | 789.95 |
| ASTRAZENECA PHARMA IND LT | 8243.90 | 107.66 | 23.61 | 20609.75 | 7630.00 | 10653.05 |
| BLISS GVS PHARMA LTD. | 438.10 | 47.26 | 4.02 | 4646.32 | 118.35 | 462.70 |
Sun Pharmaceutical Industries Ltd, headquartered in India, is a global frontrunner in the pharmaceutical sector, holding the title of the largest pharmaceutical company in India. Since its establishment in 1981, Sun Pharma has dedicated itself to manufacturing, developing, and marketing an extensive array of branded and generic formulations along with Active Pharmaceutical Ingredients (APIs). The company showcases a diverse product portfolio targeting various chronic and acute treatments, available in forms ranging from injectables to capsules. With significant achievements like being the 11th largest in the US generics market as of September 2023, and leading the Indian branded generics market, Sun Pharma continues to expand its global footprint across emerging and developed markets, including strategic acquisitions to enhance its market position. It operates around 43 manufacturing facilities worldwide and is distinguished for its comprehensive R&D capabilities, focusing on specialty/complex products development. The company's international presence is marked by a sales force of approximately 2,200 representatives, selling products in about 80 countries with a focus on areas like dermatology, ophthalmology, and onco-dermatology. Through strategic acquisitions and a focus on R&D, Sun Pharma has solidified its standing as a pivotal player in the global pharmaceutical industry, combining extensive manufacturing capabilities with a robust product portfolio to address diverse medical needs.
In the second quarter of fiscal year 2024-25, Sun Pharmaceutical Industries Ltd. reported a consolidated net profit of ₹3,040 crore, marking a 28% increase from ₹2,375 crore in the same period the previous year. Revenue from operations rose by 9% year-on-year to ₹13,291 crore, surpassing market estimates. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) grew 24% year-on-year to ₹3,939 crore, with a margin of 29.6%. Formulation sales in India increased 11% year-on-year to ₹4,265 crore, representing 32% of total sales. These robust financial results have positively influenced the Sun Pharma share price, reflecting increased investor confidence.
The 2023-24 annual report of Sun Pharmaceutical Industries Ltd. provides comprehensive insights into its financial performance and strategic initiatives. The company achieved a total income of ₹45,000 crore, registering a growth of 5% from the previous year. The report highlights Sun Pharma's focus on expanding its product portfolio, enhancing operational efficiency, and implementing cost optimisation measures. These efforts have contributed to a stable Sun Pharma share price by showcasing the company's commitment to growth and profitability.
For the fiscal year 2023-24, Sun Pharmaceutical Industries Ltd. declared a total dividend of ₹12 per share, reflecting its commitment to returning value to shareholders. This consistent dividend payout, supported by strong financial performance, has positively impacted the Sun Pharma share price by enhancing investor confidence.
1. Who is the CEO of Sun Pharma Ltd?
As of November 2024, the Managing Director of Sun Pharmaceutical Industries Ltd. is Mr. Dilip Shanghvi. He oversees the company's operations and strategic initiatives, influencing the Sun Pharma share price through effective leadership and business expansion.
2. When was Sun Pharma Ltd established?
Sun Pharmaceutical Industries Ltd. was established in 1983. Over the decades, it has grown into one of India's leading pharmaceutical companies, impacting the Sun Pharma share price through its extensive operations and market presence.
3. What factors influence Sun Pharma Ltd share price fluctuations?
The Sun Pharma share price is influenced by various factors, including the company's financial performance, expansion of product portfolios, regulatory developments, and broader economic conditions. Additionally, market demand for pharmaceutical products, competition, and research and development outcomes play significant roles in determining share price movements.
4. Is Sun Pharma debt free?
No, Sun Pharmaceutical Industries Ltd. is not entirely debt-free. The company utilises debt financing to fund its capital-intensive projects and expansion plans. However, it maintains a balanced debt-to-equity ratio, ensuring financial stability and the ability to meet its obligations without adversely affecting the Sun Pharma share price.
5. What is the CAGR of Sun Pharma share?
Over the past five years, the Compound Annual Growth Rate (CAGR) of Sun Pharma shares has been approximately 10%. This indicates a steady growth in the Sun Pharma share price, reflecting the company's consistent financial performance and strategic initiatives.
6. How has the Sun Pharma share price performed over the past year?
Over the past year, the Sun Pharma share price has experienced fluctuations influenced by market conditions and company performance. As of November 2024, the share price has shown a modest increase compared to the same period last year, reflecting investor confidence in the company's strategic direction and financial health.
Sun Pharmaceutical Industries Ltd share price is for NSE ₹ 1,804.00 & for BSE ₹ 1,804.45 as on Jun 15 2026 11:40 AM.
The market cap of Sun Pharmaceutical Industries Ltd for NSE ₹ 0.04 & for BSE ₹ 0.04 as on Jun 15 2026 11:40 AM.
The 52 Week High and Low of Sun Pharmaceutical Industries Ltd for NSE is ₹ 1,916.60 and ₹ 1,548.00 and for BSE is ₹ 1,917.15 and ₹ 1,547.25.
The 1 year returns on the stock has been 7.12%.
As on Jun 15 2026 11:40 AM the price-to-earnings (PE) ratio for Sun Pharmaceutical Industries Ltd share is 165.35.
As on Jun 15 2026 11:40 AM, the price-to-book (PB) ratio for Sun Pharmaceutical Industries Ltd share is 93.23.
You can trade in Sun Pharmaceutical Industries Ltd shares with Bajaj Broking by opening a demat account.
To buy Sun Pharmaceutical Industries Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Sun Pharmaceutical Industries Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found